EFFECT OF GEMCITABINE ON FEMALE FERTILTY – AN ANIMAL MODEL STUDY

Abstract

Background and objectives: Advances in cancer chemotherapy have led to improved survival rates and poses greater emphasis on preserving quality of life post-treatment. Gonadotoxicity is a well-recognized side effect of many cancer chemotherapeutic agents. This study was designed to evaluate the effects of gemcitabine, an antimetabolite anticancer drug, on oogenesis in Swiss albino mice and its reversibility. Methods: Thirty six inbred female Swiss albino mice in diestrous phase were selected and divided into three groups of twelve each. Groups were labelled as A, B and Control. Groups A and B received 40 mg/kg and 80 mg/kg of gemcitabine intraperitoneally. The control group received saline intraperitoneally. At the end of two weeks 6 mice were sacrificed from each group and the rest at the end of 2 months. Ovaries were studied histologically. Results: After 2 weeks, the ovaries of experimental group mice showed more number of atretic follicles as compared to control group (p<0.01). The diameter of corpus lutea was more, though a reduction in number was recorded in experimental group (p<0.05). Whereas after 2 months, both the experimental groups showed no difference in terms of atretic follicles, diameter and number of corpus lutea (p>0.05). Conclusions: These findings suggest that administration of gemcitabine may have profound effects on oogenesis and hence female fertility. This study also suggests that the effects are reversible. Keywords: Gemcitabine; Oogenesis; Swiss albino mice; atretic follicles; corpus luteum.